Shares of Calithera Biosciences Inc (NASDAQ:CALA) have received a consensus rating of “Hold” from the eight research firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $16.75.

A number of research firms have recently weighed in on CALA. ValuEngine lowered Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 3rd. BidaskClub lowered Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 18th. Finally, Zacks Investment Research lowered Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd.

Calithera Biosciences (CALA) traded up $0.17 during midday trading on Tuesday, hitting $7.07. The stock had a trading volume of 533,191 shares, compared to its average volume of 458,889. Calithera Biosciences has a 12 month low of $6.57 and a 12 month high of $20.05. The company has a market cap of $251.00, a price-to-earnings ratio of -7.14 and a beta of 2.56.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System bought a new position in Calithera Biosciences during the 2nd quarter valued at approximately $806,000. Vanguard Group Inc. raised its position in Calithera Biosciences by 29.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,199,525 shares of the biotechnology company’s stock valued at $17,813,000 after purchasing an additional 274,510 shares during the last quarter. Dupont Capital Management Corp bought a new position in Calithera Biosciences during the 3rd quarter valued at approximately $258,000. American Century Companies Inc. raised its position in Calithera Biosciences by 272.8% during the 3rd quarter. American Century Companies Inc. now owns 424,752 shares of the biotechnology company’s stock valued at $6,690,000 after purchasing an additional 310,806 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in Calithera Biosciences by 705.3% during the 2nd quarter. Wells Fargo & Company MN now owns 26,832 shares of the biotechnology company’s stock valued at $399,000 after purchasing an additional 23,500 shares during the last quarter. 72.89% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Calithera Biosciences Inc (CALA) Given Consensus Recommendation of “Hold” by Analysts” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/calithera-biosciences-inc-cala-given-consensus-recommendation-of-hold-by-analysts/1864092.html.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.